Sponsored Videos

As health technology assessments (HTA) requirements evolve and joint clinical assessments (JCA) reshape Europe, pharma companies face growing pressure to align evidence, access, and strategy earlier in development cycles.

Supply chain data across stationary and in-transit monitoring can accelerate product release and reduce waste for pharma companies.

Hear from Miranda Delatore, CoverMyMeds, on how a connected specialty access and affordability ecosystem is eliminating delays, reducing friction, and transforming the way biopharma manufacturers get patients started on life-changing therapies faster than ever before.

Streamlined hub services, clinical navigators, and data-driven field reimbursement are transforming the rare disease patient journey.

Learn how to navigate growing complexity, reduce workflow fragmentation, and design access and affordability programs that support patients throughout their treatment journey.

Across the pharmaceutical industry, coverage does not inherently mean access. As a result, the industry must overcome "policy fatigue" by rethinking access strategies, pricing models, and organizational integration to bridge the critical gap between product coverage and real-world patient access.

Biopharma manufacturers are navigating growing supply chain complexities, including increased demand for cold chain capacity, the need for sustainable shipping solutions, and the pressure to move products from FDA approval to patients as quickly as possible.

Krystal Haynes, Senior Director of Business Development, ICS, at Cencora, outlines the challenges facing cell and gene therapy manufacturers as they attempt to move products from clinical development to commercial availability.

Building effective pharmaceutical supply chain partnerships requires intentional investment in communication, internal alignment, and structured governance to navigate an increasingly volatile industry landscape.

Cindy Baksh, ConnectiveRx, discusses pharma's shift from reactive audits to real-time prevention—protecting billions in copay spend while ensuring support reaches the patients who need it most.

Chris Dowd and Lisa Prowker of ConnectiveRx discuss point-of-care marketing as the key activation layer for investments in patient access and support—it’s essential for converting dollars spent in payer negotiations and copay programs into prescriptions.

Valerie Bandy and Ryan Rotar, both from Tecsys, examine how hospital pharmacy leaders are reshaping their expectations and prioritizing value-driven partnerships over traditional transactional vendor relationships. They explore the growing shift toward self-distribution and direct purchasing, as well as how transparency and proactive communication are now essential to mitigating logistics risk and safeguarding patient care. This interview stresses technology’s role as a critical enabler of data visibility, empowering manufacturers to build long-term trust through consistent performance and shared accountability.

Discover how AI-powered patient intelligence is ushering in a new era of pharma leadership defined by clarity, speed, and knowing the “why” behind every shift.

Understand how real-time patient intelligence transforms leadership conversations from speculation and opinion battles into confident, data-backed strategy.

Learn how outdated or incomplete insights turn every decision into a high-stakes gamble that cost brands money, momentum, and internal alignment.

David Edelman, Founder & CEO of Thrivable, provides an unflinching look at why today’s most relied-upon tools, including syndicated data, social listening, gut instinct, still leave leaders navigating with a blurry, incomplete map.

This episode acts as a peek inside the modern pharma boardroom, where leaders are expected to defend billion-dollar brands with data that’s too slow, too vague, and too outdated to survive today’s market velocity.

This series kicks off by introducing David Edelman, Founder & CEO of Thrivable, who joins Pharmaceutical Executive to discuss the rising “clarity gap” that is currently putting pharma leaders under pressure.

Discover how agentic AI is reshaping life sciences commercial operations.

A panel of industry leaders share key insights supporting the integration of patient-centric strategies into current and future drug development and market access efforts.

Industry stakeholders suggest how pharmaceutical companies can proactively plan for the potential implementation of a Most Favored Nation (MFN) pricing model.

Industry experts react to the developer’s role in preparing for value-based contracting, acknowledging that innovative agreements can support access when evidence is still maturing.

A panel of key opinion leaders consider how payers and manufacturers are increasingly embracing innovative contracting models that require strong value propositions, strategic planning, and significant upfront investment in data and stakeholder alignment.

Edward Ahn, CEO of MEDIPOST, Inc., reacts to the challenge of launching orphan drugs without complete evidence, particularly given their high cost and limited patient populations, and suggests strategies that can be used to address evidence gaps, enable market access, and support long-term patient benefit.

Expert panelists emphasize the importance of trusted data sources, strong payer partnerships, economic incentives, and AI-driven insights to address skepticism and support broader reimbursement and access strategies as payers balance real-world evidence with head-to-head clinical trials in their decision-making.

In response to the rising importance of real-world evidence (RWE) in showing value to payers beyond traditional clinical trials, key opinion leaders emphasize finding cost-effective approaches, considering diverse patient populations, and using AI to pinpoint which patients will benefit most from treatment.

A panel of industry leaders emphasize the importance of early engagement with payers, real-world evidence, and value-based endpoints to ensure successful access, pricing, and long-term market viability—especially in a more complex, globally integrated reimbursement landscape.

Leading stakeholders in the industry react to how evolving US policies, payer demands, and vertical integration are reshaping market access strategy, stressing the importance of early planning and the urgency of ensuring that innovative therapies are available and affordable for patients.